Skip to main content
. 2012 Apr;86(7):3501–3512. doi: 10.1128/JVI.06435-11

Fig 6.

Fig 6

Neutralization of envelope T332 mutants by monoclonal antibody E16. (A) The production of E protein T332 variants that were not selected for by E16 in experiments described in the legend of Fig. 5 was accomplished by using WNV-GFP-backbone as described in the legend to Fig. 2. (B and C) The sensitivity of each variant to neutralization by E16 was established as previously described (57). Data are representative of two independent experiments.